Matches in Wikidata for { <http://www.wikidata.org/entity/Q98383869> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- Q98383869 description "2020 թվականի օգոստոսի 11-ին հրատարակված գիտական հոդված" @default.
- Q98383869 description "artículu científicu espublizáu n'agostu de 2020" @default.
- Q98383869 description "scientific article published on 11 August 2020" @default.
- Q98383869 description "wetenschappelijk artikel" @default.
- Q98383869 description "наукова стаття, опублікована 11 серпня 2020" @default.
- Q98383869 name "Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial" @default.
- Q98383869 name "Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial" @default.
- Q98383869 type Item @default.
- Q98383869 label "Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial" @default.
- Q98383869 label "Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial" @default.
- Q98383869 prefLabel "Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial" @default.
- Q98383869 prefLabel "Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial" @default.
- Q98383869 P1433 Q98383869-A978D1A9-6E91-423D-BF02-AD1B6DD0E21A @default.
- Q98383869 P1476 Q98383869-753F5BFE-17E4-43D5-894E-20C9A8CBBD7E @default.
- Q98383869 P2093 Q98383869-02C6C530-AE8C-40E3-B8B4-AEFE58C8C3FB @default.
- Q98383869 P2093 Q98383869-06E8BDAA-5864-48A7-8F21-50103B0FD5BE @default.
- Q98383869 P2093 Q98383869-209AEF66-2C61-4025-AD9E-E77A8E812BDC @default.
- Q98383869 P2093 Q98383869-3D389821-4209-4BC7-AB5C-2F049A42F53A @default.
- Q98383869 P2093 Q98383869-3EF92D3F-5B3E-49BF-B9C2-C25286E274DF @default.
- Q98383869 P2093 Q98383869-470182DB-CF6B-4667-A04F-CD643F384F64 @default.
- Q98383869 P2093 Q98383869-582D0905-CA15-4B51-88A4-42A89539AEEE @default.
- Q98383869 P2093 Q98383869-5D4CF9EF-3DCF-4322-B276-22074DA04627 @default.
- Q98383869 P2093 Q98383869-6A8E4062-1F6D-4903-B3EE-37CD898CD38F @default.
- Q98383869 P2093 Q98383869-6CEF9A72-C44B-4BB9-9AB2-3340A11A0E68 @default.
- Q98383869 P2093 Q98383869-794C43E2-4C6F-467E-8232-5C784AF32B9B @default.
- Q98383869 P2093 Q98383869-99DB5AB4-AA29-4874-95E1-6E46C456083F @default.
- Q98383869 P2093 Q98383869-ADA7DBBE-CB3F-415A-9A72-D8780A2FC76F @default.
- Q98383869 P2093 Q98383869-B06E7B0F-9F5E-4D40-8792-2B87B5F299C0 @default.
- Q98383869 P2093 Q98383869-B2BD493A-0019-4055-8B08-5E6EFCA5DA24 @default.
- Q98383869 P2093 Q98383869-BF540C0B-4753-4D4D-9BCB-D0EF7541EA37 @default.
- Q98383869 P2093 Q98383869-D5DE846B-BCEF-48E6-AFDC-B6A40A5935BC @default.
- Q98383869 P2093 Q98383869-DD3E6E11-067F-4B4F-A7E0-266B26504FBC @default.
- Q98383869 P2093 Q98383869-F39A77FE-B538-428E-B069-26CCE1D2B66D @default.
- Q98383869 P2093 Q98383869-FB602634-9FDE-4F3B-A083-4A11805AFF0C @default.
- Q98383869 P2093 Q98383869-FC090F9C-0529-4665-895E-D7DBF23E1796 @default.
- Q98383869 P2093 Q98383869-FCB970F1-F3D9-4147-948E-05958505F50B @default.
- Q98383869 P2860 Q98383869-1373FF10-887F-439A-9536-BA51BA50A119 @default.
- Q98383869 P304 Q98383869-634F1842-1DD7-476A-8F17-32B3D9049BD4 @default.
- Q98383869 P31 Q98383869-9A2DDFCE-7F58-4C12-9CDF-727735D10340 @default.
- Q98383869 P356 Q98383869-4A80AFAD-6886-456A-9C7A-3A0BC76AC567 @default.
- Q98383869 P577 Q98383869-5E2DD09D-1D04-4F05-B97B-714FF933ACEB @default.
- Q98383869 P698 Q98383869-A338AAB2-9DF5-47F2-8FBF-4DE0F2511851 @default.
- Q98383869 P932 Q98383869-FA5042D4-77B4-4CF5-B13A-DAC40D3C010F @default.
- Q98383869 P356 JCO.20.00505 @default.
- Q98383869 P698 32780660 @default.
- Q98383869 P1433 Q400292 @default.
- Q98383869 P1476 "Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial" @default.
- Q98383869 P2093 "Alexander Spira" @default.
- Q98383869 P2093 "Angelo Delmonte" @default.
- Q98383869 P2093 "D Ross Camidge" @default.
- Q98383869 P2093 "Dong-Wan Kim" @default.
- Q98383869 P2093 "Enriqueta Felip" @default.
- Q98383869 P2093 "Frank Griesinger" @default.
- Q98383869 P2093 "Huamao M Lin" @default.
- Q98383869 P2093 "Hye Ryun Kim" @default.
- Q98383869 P2093 "James C H Yang" @default.
- Q98383869 P2093 "Ji-Youn Han" @default.
- Q98383869 P2093 "Ki Hyeong Lee" @default.
- Q98383869 P2093 "Marcello Tiseo" @default.
- Q98383869 P2093 "Maria Rosario García Campelo" @default.
- Q98383869 P2093 "Maximilian J Hochmair" @default.
- Q98383869 P2093 "Michael J Hanley" @default.
- Q98383869 P2093 "Myung-Ju Ahn" @default.
- Q98383869 P2093 "Neeraj Gupta" @default.
- Q98383869 P2093 "Pingkuan Zhang" @default.
- Q98383869 P2093 "Quanhong Ni" @default.
- Q98383869 P2093 "Raffaele Califano" @default.
- Q98383869 P2093 "Sanjay Popat" @default.
- Q98383869 P2093 "Scott N Gettinger" @default.
- Q98383869 P2860 Q27851440 @default.
- Q98383869 P304 "JCO2000505" @default.
- Q98383869 P31 Q13442814 @default.
- Q98383869 P356 "10.1200/JCO.20.00505" @default.
- Q98383869 P577 "2020-08-11T00:00:00Z" @default.
- Q98383869 P698 "32780660" @default.
- Q98383869 P932 "7605398" @default.